Compare WTI & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WTI | YDES |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.5M | 422.9M |
| IPO Year | 2004 | 2024 |
| Metric | WTI | YDES |
|---|---|---|
| Price | $3.35 | $5.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.23 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 102.6K |
| Earning Date | 10-29-2026 | 08-31-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $487,096,000.00 | N/A |
| Revenue This Year | $23.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $1.70 |
| 52 Week High | $5.08 | $15.72 |
| Indicator | WTI | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 42.35 |
| Support Level | $3.11 | $4.69 |
| Resistance Level | $3.87 | $5.15 |
| Average True Range (ATR) | 0.20 | 0.82 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 37.09 | 0.00 |
W&T Offshore Inc is an an independent oil, NGL and natural gas producer with all of its operations offshore in the Gulf of America. The company is active in the exploration, development and acquisition of oil and natural gas properties. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion. The company has its operations in Mississippi Canyon; Ewing Bank; Ship Shoal; Garden Banks; and Mobile Bay Complex.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.